Benzene Ring Is Part Of A Substituent Which Contains Nitrogen Patents (Class 514/597)
  • Patent number: 10125117
    Abstract: Disclosed herein is an in vitro or in vivo method of activating or reversing inactivation of acetylcholinesterase (AChE) or butyrylcholinesterase (BuchE) using compounds of the present disclosure. Also disclosed is a method of treating a subject exposed to a nerve agent using such compounds. Also disclosed is a method of treating organophosphate poisoning in a subject using such compounds. Also disclosed is a method of modulating neuronal signaling and transmission in a subject using such compounds.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: November 13, 2018
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Milan Stojanovic, Francine Katz, Donald W. Landry
  • Publication number: 20150148301
    Abstract: The present invention relates to inhibitors of the activity of Complex (III) of the mitochondrial electron transport chain and use thereof in treatment and/or prevention of cancers presenting tumour-initiating cells. The present invention further relates to pharmaceutical compositions containing said inhibitors alone or in combination with other pharmaceutically active agents, and their use as medicaments or as agrochemicals where their properties as inhibitors of the mitochondrial respiration is of benefit.
    Type: Application
    Filed: May 23, 2013
    Publication date: May 28, 2015
    Inventors: Virginie Clement-Schatlo, Thomas Fessard, Damien Barbaras, Joana Matos, Erick Carreira
  • Publication number: 20150056164
    Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
    Type: Application
    Filed: April 24, 2014
    Publication date: February 26, 2015
    Applicant: AbbVie Inc.
    Inventors: David A. Betebenner, John K. Pratt, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Douglas K. Hutchinson, Warren M. Kati, Allan C. Krueger, Kenton L. Longenecker, Clarence J. Maring, John T. Randolph, Todd W. Rockway, Michael D. Tufano, Rolf Wagner, Dachun Liu
  • Patent number: 8921426
    Abstract: A cationic bis-urea compound is disclosed of formula (1): wherein: each m is independently an integer of 0 to 4, each k is independently 0 or 1, each Z? is a monovalent radical independently selected from the group consisting of hydroxyl (*—OH), carboxyl (*—COOH), cyano (*—CN), nitro (*—NO2), sulfonate (*—SO3?), trifluoromethyl (*—CF3), halides, amine groups, ketone groups, alkyl groups comprising 1 to 6 carbons, alkoxy groups comprising 1 to 6 carbons, thioether groups comprising 1 to 6 carbons, and combinations thereof, each L? is independently a divalent alkylene group comprising 1 to 6 carbons, wherein a *-[-L?-]k- is a single bond when k is 0, each Y? is independently a monovalent non-polymeric radical comprising a positive charged amine, and each X? is independently a negative charged counterion.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: December 30, 2014
    Assignees: International Business Machines Corporation, Agency For Science, Technology And Research
    Inventors: Daniel Joseph Coady, Amanda Catherine Engler, Kazuki Fukushima, James Lupton Hedrick, Shaoqiong Liu, Hareem Tariq Maune, Alshakim Nelson, Jed Walter Pitera, Yi Yan Yang
  • Patent number: 8912214
    Abstract: Described herein are Chk2-inhibitor compounds and derivatives thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions thereof.
    Type: Grant
    Filed: July 27, 2006
    Date of Patent: December 16, 2014
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Yves Pommier, Robert H. Shoemaker, Dominic Scudiero, Michael Currens, John Cardellina, Andrew Jobson
  • Publication number: 20140348926
    Abstract: The application discloses a formulation and method for increasing bioavailability of an orally administered drug.
    Type: Application
    Filed: January 17, 2013
    Publication date: November 27, 2014
    Inventors: Amnon Hoffman, Abraham J. Domb, Anna Elgart, Irina Cherniakov
  • Publication number: 20140275037
    Abstract: Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel semicarbazides, sulfonyl carbazides, ureas and related compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to Arenaviridae (Junin, Machupo, Guanavito, Sabia and Lassa), Filoviridae (ebola and Marburg viruses), Flaviviridae (yellow fever, omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever).
    Type: Application
    Filed: December 19, 2013
    Publication date: September 18, 2014
    Applicant: Siga Technologies, Inc.
    Inventors: Yijun Deng, Theodore J. Nitz, Thomas R. Bailey, Yanming Zhang, Sylvie Laquerre
  • Publication number: 20140256819
    Abstract: The present invention relates to compounds of formula I or a pharmaceutically acceptable salts thereof; wherein the variables R1-R5, Ar1, and X are as defined herein. The compounds are capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: March 6, 2014
    Publication date: September 11, 2014
    Applicant: Allergan, Inc.
    Inventors: Thomas C. Malone, C. Eugene Hull, III
  • Publication number: 20140200239
    Abstract: The present invention provides new compounds of formula I, II or III, which have Src homology-2 containing protein tyrosine phosphatase-1 (SHP-1) agonist activity. Also provided are treatment methods using the compounds of formula I, II or III.
    Type: Application
    Filed: August 3, 2012
    Publication date: July 17, 2014
    Applicant: National Taiwan University
    Inventors: Chung-Wai Shiau, Kuen-Feng Chen
  • Publication number: 20140148482
    Abstract: The present application provides a method for screening compounds for cancer treatment comprising treating cancer cells with a candidate compound for sufficient time for detectable expression of a gene selected from GADD45 family; and detecting the level of expression of the gene as compared to the level of expression in the absence of the candidate compound; wherein an increased level of expression in the presence of the candidate compound as compared to expression in the absence of the candidate compound indicates that the candidate compound acts as an inhibitor of the cancer cells. In some embodiments, the method can be used for screening compounds for treatment of sorafenib-resistant hepatocellular carcinoma. The present application further provides a method for treating hepatocellular carcinoma comprising administering to a subject having hepatocellular carcinoma a therapeutic effective amount of an agonist of GADD45 family.
    Type: Application
    Filed: November 14, 2013
    Publication date: May 29, 2014
    Applicant: National Taiwan University
    Inventors: Da-Liang Ou, Chung-Wai Shiau, Chiun Hsu
  • Publication number: 20140088056
    Abstract: The invention provides for a method of inhibiting interferon-beta gene expression and/or reducing the level of interferon-beta in a cell by contacting the cell with a Na+, Ca2+, or K+ ion-channel modulator. The invention also provides for a method of treating a disease or disorder characterized by elevated interferon beta levels or elevated levels of interferon-beta gene expression. Additionally, the invention provides a method for treating pathogenic or non-pathogenic infections.
    Type: Application
    Filed: September 28, 2011
    Publication date: March 27, 2014
    Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Junqiang Ye, Shuibing Chen, Tom Maniatis
  • Publication number: 20130338231
    Abstract: The invention provides compound of the general formula: in which each X independently represents a polymer chain; n represents an integer greater than 1; Q represents a linker; Y represents an amide group; and Z represents either —CH.(CH2L)2 or —C(CH2L)(?CH2), in which each L independently represents a leaving group. The compounds are useful reagents for the conjugation of polymers to proteins, the resulting conjugates being novel and also forming part of the invention.
    Type: Application
    Filed: June 17, 2013
    Publication date: December 19, 2013
    Inventors: Antony GODWIN, Stephen Brocchini
  • Patent number: 8598233
    Abstract: Compositions and methods for administering memantine to a subject are provided. In particular, a solid pharmaceutical composition in a unit dosage form for once daily oral administration is provided. The compositions comprises an extended release formulation of 22.5 mg to 33.75 mg memantine, or a pharmaceutically acceptable salt thereof, wherein administration of a dose of the composition to a human subject provides a mean plasma memantine concentration profile characterized by a change in memantine concentration as a function of time (dC/dT) that is less than 50% of the dC/dT provided by the same quantity of an immediate release form of memantine, determined in a time period between 0 hours to 6 hours after administration of memantine, and wherein dC/dT is measured in a single-dose human PK study. Methods of treating dementia, in particular Alzheimer's diseases, using the compositions are provided.
    Type: Grant
    Filed: January 28, 2013
    Date of Patent: December 3, 2013
    Assignee: Adamas Pharmacueticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson
  • Patent number: 8580858
    Abstract: The invention provides compositions comprising extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: November 12, 2013
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson
  • Patent number: 8580857
    Abstract: A method for determining a therapeutically effective amount of suramin for administering to a patient, who is to receive a cytotoxic agent, which comprises the steps of determining the circulating suramin concentration in the patient; administering suramin, if required, to establish a low circulating concentration of suramin in the patient of below about 200 ?M; and administering the chemotherapeutic agent to the patient when the low circulating concentration of suramin is present in the patient. Conveniently a nomogram can be constructed for use in clinical settings with the suramin.
    Type: Grant
    Filed: February 21, 2011
    Date of Patent: November 12, 2013
    Inventors: Jessie L. -S. Au, M. Guillaume Wientjes
  • Publication number: 20130281515
    Abstract: A cationic bis-urea compound is disclosed of formula (1): wherein: each m is independently an integer of 0 to 4, each k is independently 0 or 1, each Z? is a monovalent radical independently selected from the group consisting of hydroxyl (*—OH), carboxyl (*—COOH), cyano (*—CN), nitro (*—NO2), sulfonate (*—SO3?), trifluoromethyl (*—CF3), halides, amine groups, ketone groups, alkyl groups comprising 1 to 6 carbons, alkoxy groups comprising 1 to 6 carbons, thioether groups comprising 1 to 6 carbons, and combinations thereof, each L? is independently a divalent alkylene group comprising 1 to 6 carbons, wherein a *-[-L?-]k- is a single bond when k is 0, each Y? is independently a monovalent non-polymeric radical comprising a positive charged amine, and each X? is independently a negative charged counterion.
    Type: Application
    Filed: April 18, 2012
    Publication date: October 24, 2013
    Applicants: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, INTERNATIONAL BUSINESS MACHINES CORPORATION
    Inventors: Daniel Joseph Coady, Amanda Catherine Engler, Kazuki Fukushima, James Lupton Hedrick, Shaoqiong Liu, Hareem Tariq Maune, Alshakim Nelson, Jed Walter Pitera, Yi Yan Yang
  • Publication number: 20130261120
    Abstract: The present invention relates to: *combinations of: component A: one or more omega-carboxyaryl-substituted diphenyl urea compounds of general formula (I), or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof; component B: one or more N-(2-arylamino) aryl sulfonamide compounds of general formula (II), or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof; and, optionally, component C: one or more further pharmaceutical agents; in which optionally some or all of the components are in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially. dependently of one another by the oral, intravenous, topical, local installations, intraperitoneal or nasal route; *use of such combinations for the preparation of a medicament for the treatment or prophylaxis of a cancer; and *a kit comprising such a combination.
    Type: Application
    Filed: September 29, 2011
    Publication date: October 3, 2013
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Florian Pühler, Marion Hitchcock
  • Publication number: 20130244944
    Abstract: Provided herein are self-assembling compounds that can form ion channels in lipid bilayers or cell membranes and ion-channel-forming compositions comprising the self-assembling compounds. Also provided are methods of making and using the ion channels formed from a plurality of molecules of the self-assembling compounds. Further, provided are methods of treating or preventing conditions and diseases that are related to the dysfunction of ion channels, including chloride channels.
    Type: Application
    Filed: December 31, 2012
    Publication date: September 19, 2013
    Applicants: VERSITECH LIMITED, THE UNIVERSITY OF HONG KONG
    Inventors: Dan Yang, Xiang Li, Huiyan Zha
  • Publication number: 20130245037
    Abstract: The present invention relates to methods of stabilizing the alpha subunit of hypoxia inducible factor (HIF). The invention further relates to methods of preventing, pretreating, or treating conditions associated with HIF, including ischemic and hypoxic conditions. Compounds for use in these methods are also provided.
    Type: Application
    Filed: May 17, 2013
    Publication date: September 19, 2013
    Applicant: FibroGen, Inc.
    Inventors: Volkmar Guenzler-Pukall, Thomas B. Neff, Qingjian Wang, Michael P. Arend, Lee A. Flippin, Alex Melekhov
  • Patent number: 8497306
    Abstract: The invention relates to pharmaceutically acceptable salts of guanylhydrazone-containing compounds, for example, Semapimod. The invention also relates to pharmaceutically acceptable compositions comprising the salts and methods for their use.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: July 30, 2013
    Assignee: Ferring B.V.
    Inventor: Thais M. Sielecki-Dzurdz
  • Publication number: 20130190396
    Abstract: Therapeutic ureido-sulfonamide compositions having compounds with the formula R-Q-Ar—SO2NH2 are disclosed, which compounds selectively inhibit CAIX and CAXII, and which are effective to inhibit hypoxic tumor growth, suppress metastases, and impair and deplete cancer stem cells in mammals.
    Type: Application
    Filed: January 9, 2013
    Publication date: July 25, 2013
    Applicant: METASIGNAL THERAPEUTICS INC.
    Inventor: METASIGNAL THERAPEUTICS INC.
  • Patent number: 8487004
    Abstract: A method for treating a neurofibroma, e.g. dermal neurofibroma, a subdermal neurofibroma, or a superficial plexiform neurofibroma, in a subject in need of such treatment is disclosed. The method comprises locally applying a composition to a neurofibroma either topically or intralesionally. This method does not encompass systemic administration of the composition to the subject to have an effect on the neurofibromas. Compositions useful for such treatments and methods of preparing the compositions are disclosed.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: July 16, 2013
    Assignee: Nexgenix Pharmaceuticals, Inc.
    Inventors: Ruihong Chen, Allan E. Rubenstein, Xiaodong Shen, Scott Stewart, Jin-Chen Yu
  • Patent number: 8486381
    Abstract: The present invention relates to methods for treating intestinal fluid balance disorders and modulating intestinal fluid secretion and absorption using calcimimetics and calcilytics.
    Type: Grant
    Filed: August 28, 2006
    Date of Patent: July 16, 2013
    Assignee: Amgen Inc.
    Inventors: John Peter Geibel, Steven Charles Hebert, David Martin, Deborah A. Russell
  • Publication number: 20130178494
    Abstract: The present disclosure relates to new DNA-directed alkylating agents and water-soluble N-mustard agents with improved chemical stability and anti-tumor therapeutic efficacy.
    Type: Application
    Filed: June 29, 2012
    Publication date: July 11, 2013
    Applicant: Academia Sinica
    Inventors: Tsann-Long SU, Ting-Chao Chou, Te-Chuang Lee
  • Publication number: 20130137706
    Abstract: The present invention provides methods of inhibiting the growth of Mycobacterium species or treating an animal having a Mycobacterium infection (including multi-drug resistance strains and extensively drug resistant strains) by administering a compound of the invention, a salt thereof, or a composition comprising the same.
    Type: Application
    Filed: October 23, 2012
    Publication date: May 30, 2013
    Applicant: POLYMEDIX, INC.
    Inventor: POLYMEDIX, INC.
  • Patent number: 8420669
    Abstract: The present disclosure relates to 4-(2-amino-1-hydroxyethyl)phenol derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the BETA2 adrenergic receptor.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: April 16, 2013
    Assignee: Laboratories Almirall, S.A.
    Inventors: Carlos Puig Duran, Maria Isabel Crespo Crespo, Julio Cesar Castro Palomino Laria, Silvia Gual Roig, Eloisa Navarro Romero
  • Publication number: 20130072551
    Abstract: The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.
    Type: Application
    Filed: November 16, 2012
    Publication date: March 21, 2013
    Applicant: UNIVERSITE VICTOR SEGALEN - BORDEAUX 2
    Inventor: Universite Victor Segalen-Bordeaux 2
  • Patent number: 8399507
    Abstract: Tricyclic compounds containing a cyclopropanecarboxylic acid fused to a bicyclic ring, including pharmaceutically acceptable salts, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: March 19, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Gui-Bai Liang, Xibin Liao, Weiguo Liu, Paul E. Finke, Dooseop Kim, Lihu Yang, Songnian Lin
  • Publication number: 20130065963
    Abstract: The invention provides novel classes of HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided as well as methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention.
    Type: Application
    Filed: July 17, 2012
    Publication date: March 14, 2013
    Applicant: Georgetown University
    Inventors: Alan P. Kozikowski, Anatoly Dritschilo, Mira Jung, Pavel A. Petukhov, Bin Chen
  • Publication number: 20130053392
    Abstract: A carbonic anhydrase IX (CA IX) inhibitor which comprises a compound of general formula: R—NH—CX—NH—(CH2)n—Ar-Q-SO2—NH2 or a pharmaceutically-acceptable salt, derivative or prodrug thereof; wherein n=0, 1 or 2; Q is O or NH; X is O or S; and R comprises an organic substituent group.
    Type: Application
    Filed: February 14, 2011
    Publication date: February 28, 2013
    Inventors: Peter Ebbesen, Claudlu T. Supuran, Andrea Scozzafava, Erik Olai Pettersen, Kaye Williams, Ludwig Dubois, Philippe Lambin
  • Patent number: 8362085
    Abstract: The invention provides methods for administering memantine to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt is administered to a patient suffering from a neurological condition, such as Alzheimer's disease, Parkinson's disease or dementia. The extended release form achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: January 29, 2013
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson
  • Publication number: 20130005803
    Abstract: The use of compounds in the treatment of skin disorders is described. In particular, the use of a compound of formula (I) or one of its pharmaceutically acceptable salts, pharmaceutically acceptable solvates or hydrates in the preparation of a medicament to treat inflammatory skin pathologies is described.
    Type: Application
    Filed: December 15, 2010
    Publication date: January 3, 2013
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventor: Jérôme Aubert
  • Patent number: 8343963
    Abstract: The present invention relates to novel sulfamoyl-phenyl-ureido compounds having the formula (I) or a physiologically acceptable salt or derivative thereof which are suitable for the therapy of infections caused by protozoa and in particular uncomplicated or severe malaria caused by plasmodia.
    Type: Grant
    Filed: January 29, 2010
    Date of Patent: January 1, 2013
    Assignee: 4SC AG
    Inventor: Stefano Pegoraro
  • Publication number: 20120329786
    Abstract: The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, and other complications associated with these diseases and disorders.
    Type: Application
    Filed: August 31, 2012
    Publication date: December 27, 2012
    Applicant: Myrexis, Inc.
    Inventors: J. Adam Willardsen, Jeffrey W. Lockman, Brett R. Murphy, Weston R. Judd, In Chul Kim, Se-Ho Kim, Daniel Feodore Zigar, Kraig M. Yager, Tracey C. Fleischer, Ryan T. Terry-Lorenzo, J. Jay Boniface, Daniel P. Parker, Ian A. McAlexander, Matthew Gregory Bursavich, David M. Dastrup
  • Patent number: 8338486
    Abstract: The invention provides methods for administering extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil is administered to a patient suffering from a neurological condition, such as Alzheimer's disease, Parkinson's disease or dementia. The extended release form of memantine achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: December 25, 2012
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson
  • Patent number: 8338485
    Abstract: The invention provides compositions comprising extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: December 25, 2012
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson
  • Patent number: 8329752
    Abstract: The invention provides compostions for administering memantine to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: December 11, 2012
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson
  • Publication number: 20120282353
    Abstract: The present invention generally relates to the modulation of hypoxia-inducible factor (HIF) using the compounds and methods disclosed herein. These compounds and methods can be applied to the prevention, pretreatment, and/or treatment of conditions or states associated with HIF, such as hypoxia- and ischemia-related conditions and the induction of stasis.
    Type: Application
    Filed: March 26, 2012
    Publication date: November 8, 2012
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Mark B. Roth, Mark Budde
  • Patent number: 8293794
    Abstract: The present invention provides novel methods and compositions for the treatment and prevention of CNS-related conditions. One of the CNS-related conditions treated by the methods and compositions of the invention is Alzheimer's disease.
    Type: Grant
    Filed: April 2, 2010
    Date of Patent: October 23, 2012
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson
  • Publication number: 20120264703
    Abstract: The present invention provides novel methods and formulations for treating anxiety disorders, including Post Traumatic Stress Disorder, in human subjects employing coordinate treatment using ? and ? blockers alone or in combination with additional psychotherapeutic medications to treat the anxiety disorder and reduce symptomology in treated subjects.
    Type: Application
    Filed: June 15, 2012
    Publication date: October 18, 2012
    Inventors: Arifulla Khan, John Frederick Reinhard, JR.
  • Patent number: 8283379
    Abstract: The present invention provides novel methods and compositions for the treatment and prevention of CNS-related conditions. One of the CNS-related conditions treated by the methods and compositions of the invention is Alzheimer's disease.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: October 9, 2012
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson
  • Publication number: 20120214785
    Abstract: The invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Application
    Filed: August 17, 2011
    Publication date: August 23, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Gerald Juergen ROTH, Martin FLECK, Niklas HEINE, Joerg KLEY, Thorsten LEHMANN-LINTZ, Heike NEUBAUER, Bernd NOSSE
  • Publication number: 20120184520
    Abstract: [Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that a compound of the present invention or a salt thereof exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. The present invention further relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound of the present invention or a salt thereof, and an excipient.
    Type: Application
    Filed: September 15, 2010
    Publication date: July 19, 2012
    Applicant: Astellas Pharma Inc.
    Inventors: Kousei Yoshihara, Daisuke Suzuki, Susumu Yamaki, Yuji Koga, Norio Seki, Jiro Fujiyasu, Masahiro Neya
  • Patent number: 8222297
    Abstract: New aniline or phenol N-mustards linked to DNA-affinity carriers (such as 9-anilinoacridines, acridines and quinolines), aminobenzamides or aminophenol ethers by a urea, carbamic acid, carbanic acid ester, hydrazineurea, hydrazinecarbamic acid ester, phenoxyurea, phenoxycarbamic acid ester linkage with improved chemical stability and anti-tumor therapeutic efficacy are provided.
    Type: Grant
    Filed: January 11, 2008
    Date of Patent: July 17, 2012
    Assignee: Academia Sinica
    Inventors: Tsann-Long Su, Ting-Chao Chou
  • Patent number: 8173841
    Abstract: This invention relates to tetrahydro-naphthalene derivatives and salts thereof which are useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, urge urinary incontinence, chronic pain, neuropathic pain, post-operative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: May 8, 2012
    Assignee: Xention Limited
    Inventors: Masaomi Tajimi, Toshio Kokubo, Masahiro Shiroo, Yasuhiro Tsukimi, Takeshi Yura, Klaus Urbahns, Noriyuki Yamamoto, Muneto Mogi, Hiroshi Fujishima, Tsutomu Masuda, Nagahiro Yoshida, Toshiya Moriwaki
  • Patent number: 8173708
    Abstract: The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: May 8, 2012
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson
  • Patent number: 8168209
    Abstract: The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: May 1, 2012
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Publication number: 20120082646
    Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
    Type: Application
    Filed: March 25, 2010
    Publication date: April 5, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: David A. Betebenner, John K. Pratt, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Douglas K. Hutchinson, Warren M. Kati, Allan C. Krueger, Kenton L. Longenecker, Clarence J. Maring, John T. Randolph, Todd W. Rockway, Michael D. Tufano, Rolf Wagner, Dachun Liu
  • Patent number: 8088826
    Abstract: This invention relates to tetrahydro-Naphthalene derivatives and salts thereof which are useful as an active ingredient of pharmaceutical preparations. The tethrahydro—Naphthalene derivatives of the present invention have excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, urge urinary incontienence, chronic pain, neuropathic pain, post-operative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD.
    Type: Grant
    Filed: April 15, 2008
    Date of Patent: January 3, 2012
    Assignee: Xention Limited
    Inventors: Masaomi Tajimi, Toshio Kokubo, Masahiro Shiroo, Yasuhiro Tsukimi, Takeshi Yura, Klaus Urbahns, Noriyuki Yamamoto, Muneto Mogi, Hiroshi Fujishima, Tsutomu Masuda, Nagahiro Yoshida, Toshiya Moriwaki
  • Publication number: 20110312920
    Abstract: Method of identifying compounds that modulate intermolecular interactions between a target protein and a modifier are disclosed. Pharmaceutical composition comprising compounds that inhibit intermolecular interactions between a target protein and a modifier are disclosed. Methods of treating individual suffering from inflammatory conditions, undesirable immune responses, immunological conditions and bacterial infections are disclosed.
    Type: Application
    Filed: July 29, 2011
    Publication date: December 22, 2011
    Inventors: Ramachandran Murali, Mark I. Greene